NASDAQ · DERM

Journey Medical Corporation

$6.39 +$0.20 (+3.23%) 1D Market open

Key Metrics

$170.44M
Market cap
P/E · TTM
$64.68M
Revenue · TTM
−$9.59M
Net income
EPS · TTM $-0.42
Dividend yield
Free cash flow
Beta · 1Y 1.94
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 14
    The stock moved +22.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 14
  • Mar 30
    From its Feb 25 high, the share price fell 50%.

    Peak close $8.73 on Feb 25; trough close $4.39 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -50%
  • Mar 26
    The stock moved -30.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$170.44M
Enterprise value$168.59M
Shares outstanding27.5M
52-wk range$4.31 – $9.56
Avg volume · 20D119.4K
Net cash $1.85M
Book value / share$1.36
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Journey Medical Corporation
IPO dateNov 12, 2021
Employees58

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.64
P/FCF
EV/EBITDA
EV/Sales2.61
Graham №

Profitability

Gross
Operating -14.7%
Net -14.8%
FCF
ROE / ROIC -37.7% · —

Financial Health

Current ratio1.72
Quick ratio1.47
Debt / equity0.82
Debt / EBITDA
Net cash $1.85M
Working capital$27.14M

Cash Flow · TTM

Operating CF −$6.70M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

0.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings